PS
KROS icon

Principal Securities’s Keros Therapeutics KROS Stock Holding History

Principal Securities’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-86
Closed -$1.36K – 2553
2025
Q3 		$1.36K Buy
86
+27
+46% +$399 ﹤0.01% 3321
2025
Q2 		$788 Buy
+59
New +$797 ﹤0.01% 3391
2024
Q2 		– Sell
-3
Closed -$199 – 3443
2024
Q1 		$199 Sell
3
-41
-93% -$2.43K ﹤0.01% 3242
2023
Q4 		$1.75K Buy
+44
New +$1.38K ﹤0.01% 2843

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Principal Securities's KROS Position: Q4 2025 in Review

Principal Securities sold out of Keros Therapeutics (KROS) in Q4 2025, closing a stake of 86 shares — an estimated $1.36K sold.

Principal Securities first reported a position in KROS in Q4 2023 and held it in 4 quarters. The position peaked at $1.75K in Q4 2023. 166 funds tracked by Wall St. Rank hold KROS as of Q4 2025.

  • Principal Securities reported no remaining Keros Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 86 Keros Therapeutics shares in Q4 2025, an estimated $1.36K.
  • Principal Securities first reported a position in Keros Therapeutics in Q4 2023 and held it in 4 quarters.
  • Principal Securities's Keros Therapeutics position peaked at $1.75K in Q4 2023.
  • 166 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.